Rosenstock J, Riddle MC: Insulin therapy in type 2 diabetes. The CADRE handbook of diabetes management. Edited by: Cefalu WT, Gerich JE, Leroith D. 2004, New York: Medical Information Press, 145-168.
Google Scholar
Chacra AR, Davidson JA, Diaz J, Escalante-Pulido M, Litwak LE, Mestman JH, More L, Violante RM: An algorithm for the treatment of type 2 diabetes in Latin America. Diabetes Obes Metab. 2005, 7: 148-160. 10.1111/j.1463-1326.2004.00380.x.
Article
CAS
PubMed
Google Scholar
Holst JJ, Knop FK, Vilsbøll T, Krarup T, Madsbad S: Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diabetes Care. 2011, 34 (Suppl2): S251-S257.
Article
CAS
PubMed
PubMed Central
Google Scholar
Drucker DJ: The role of gut hormones in glucose homeostasis. J Clin Invest. 2007, 117: 24-32. 10.1172/JCI30076.
Article
CAS
PubMed
PubMed Central
Google Scholar
Covington P, Christopher R, Davenport M, Fleck P, Mekki QA, Wann ER, Karim A: Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase–4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther. 2008, 30 (3): 499-512. 10.1016/j.clinthera.2008.03.004.
Article
CAS
PubMed
Google Scholar
Christopher R, Covington P, Davenport M, Fleck P, Mekki QA, Wann ER, Karim A: Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase–4 inhibitor alogliptin in healthy male subjects. Clin Ther. 2008, 30 (3): 513-527. 10.1016/j.clinthera.2008.03.005.
Article
CAS
PubMed
Google Scholar
Wilmington N.C. PPD, Inc. (Nasdaq: PPDI): PPD confirms Takeda receives NDA approval of NESINA® (alogliptin) from Japanese ministry of health, labour and welfare. Available from:http://files.shareholder.com/downloads/PPDI/ebec798d14b9/PPDI.pdf,
Insight Pharma reports: executive summary. Accessed in 2012. Available from:http://www.insightpharmareports.com/uploadedFiles/ExecutiveSummary,
Viereck C, Boudes P: An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development. Contemp Clin Trials. 2011, 32 (3): 324-332. 10.1016/j.cct.2011.01.009.
Article
PubMed
Google Scholar
Choe C, Edelman S: New therapeutic options for treating type-2 diabetes: a review of insulin analogs and premixed insulin analogs. J Natl Med Assoc. 2007, 99 (4): 357-367.
PubMed
PubMed Central
Google Scholar
GooBen K, Gra¨ber S: Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab. 2012, 14 (12): 1061-1072.
Article
Google Scholar
Conversion of units of glucose plasmatic level. Accessed in 2012. Available from:http://en.mte.cz/conversion.php,
Rosenstock R, Rendell MS, Gross JL, Fleck PR, Wilson CA, Mekki Q: Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without causing weight gain or increased hypoglycemia. Diabetes Obes Metab. 2009, 11: 1145-1152. 10.1111/j.1463-1326.2009.01124.x. Study 1
Article
CAS
PubMed
Google Scholar
Sterne JAC, Sutton AJ, Ioannidis JPA, Terrin N, Jones DR, Lau J, Carpenter J, Rücker G, Harbord RM, Schmid CH, Tetzlaff J, Deeks JJ, Peters J, Macaskill P, Schwarzer G, Duva S, Altman DG, Moher D, Higgins JP: Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011, 342: d4002-10.1136/bmj.d4002.
Article
Google Scholar
Moher D, Liberati A, Tetzlaff J, Altman DG, and the PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009, 6 (7): e1000097-10.1371/journal.pmed.1000097. Available from:http://medicine.plosjournals.org/,
Article
PubMed
PubMed Central
Google Scholar
Review manager (RevMan) [computer program]. version 5.1. Copenhagen: the Nordic Cochrane centre, the Cochrane collaboration. 2011, Available fromhttp://ims.cochrane.org/revman,
Borenstein M, Hedges L, Higgins J, Rothstein H: Comprehensive meta-analysis version 2. 2005, Englewood NJ: Biostat
Google Scholar
Bosi E, Ellis GC, Wilson CA, Fleck PR: Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52 week, randomized, double-blind, active-controlled, parallel-group study. Diabetes Obes Metab. 2011, 13: 1088-1096. 10.1111/j.1463-1326.2011.01463.x.
Article
CAS
PubMed
Google Scholar
Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q, and for the alogliptin Study 008 Group: Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomized, double-blind, placebo-controlled study. Int J Clin Pract. 2009, 63 (1): 46-55. 10.1111/j.1742-1241.2008.01933.x.
Article
CAS
PubMed
Google Scholar
Pratley RE, Reusch JEB, RWilson CA FP, Mekki Q: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin. 2009, 25 (10): 2361-2371. 10.1185/03007990903156111. Study 1
Article
CAS
PubMed
Google Scholar
Pratley RE, Kipnes MS, Fleck PR, Wilson C, Mekki Q: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab. 2009, 11: 167-176. 10.1111/j.1463-1326.2008.01016.x. Study 2
Article
CAS
PubMed
Google Scholar
Defronzo RA, Fleck PR, Wilson CA, Mekki Q: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control. Diabetes Care. 2008, 31: 2315-2317. 10.2337/dc08-1035.
Article
CAS
PubMed
PubMed Central
Google Scholar
Rosenstock J, Inzucchi SE, Seufert J, Fleck PR, Wilson CA, Mekki Q: Initial combination therapy with alogliptin and pioglitazone in drug-naı¨ve patients with type 2 diabetes. Diabetes Care. 2010, 33: 2406-2408. 10.2337/dc10-0159. Study 2
Article
CAS
PubMed
PubMed Central
Google Scholar
Kaku K, Itayasu T, Hiroi S, Hirayama M, Seino Y: Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study. Diabetes Obes Metab. 2011, 13: 1028-1035. 10.1111/j.1463-1326.2011.01460.x.
Article
CAS
PubMed
Google Scholar
Seino Y, Fujita T, Hiroi S, Hirayama M, Kaku K: Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study. Curr Med Res Opin. 2011, 9: 1781-1792. Study 1
Article
Google Scholar
Seino Y, Fujita T, Hiroi S, Hirayama M, Kaku K: Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension. Curr Med Res Opin. 2011, 27 (S3): 21-29. 10.1185/03007995.2011.614936. Study 2
Article
CAS
PubMed
Google Scholar
Esposito R, Cozzolino D, Bellastella G, Maiorino MI, Chiodini P, Ceriello A, Giugliano D: Dipeptidyl peptidase-4 inhibitors and HbA1c target of < 7% in type 2 diabetes: Meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2011, 13: 594-603. 10.1111/j.1463-1326.2011.01380.x.
Article
CAS
PubMed
Google Scholar
Triplitt CL, Reasner CA, Isley WL: Diabetes mellitus. Pharmacotherapy, a pathophysiologic approach. Edited by: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. 2005, New York: McGraw-Hill, 1333-63. 6
Google Scholar
Nathan DM, Singer DE, Hurxthal K, Goodson JD: The clinical information value of the glycosylated hemoglobin assay. N Engl J Med. 1984, 310: 341-346. 10.1056/NEJM198402093100602.
Article
CAS
PubMed
Google Scholar
Fanelli D: How many scientists fabricate and falsify research? a systematic review and meta-analysis of survey data. PLoS One. 2009, 4 (5): e5738-10.1371/journal.pone.0005738.
Article
PubMed
PubMed Central
Google Scholar
Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE: Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007, 30: 1979-1987. 10.2337/dc07-0627.
Article
CAS
PubMed
Google Scholar
Ioannidis JPA: Why most published research findings are false. PLoS Med. 2005, 2 (8): e124-10.1371/journal.pmed.0020124.http://www.plosmedicine.org/article/info:doi/10.1371/,
Article
PubMed
PubMed Central
Google Scholar
de Visser SJ, Uchida N, van Vliet-Daskalopoulou E, Fukazawa I, van Doorn MBA, van den Heuvel MW, Machielsen CSM, Uchida E, Cohen AF: Pharmacokinetic differences between Caucasian and Japanese subjects after single and multiple doses of a potential combined oral contraceptive (Org 30659 and EE). Contraception. 2003, 68: 195-202. 10.1016/S0010-7824(03)00140-9.
Article
CAS
PubMed
Google Scholar
Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, Moore R, Lee C, Chen Y, Schneck D: Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther. 2005, 78: 330-41. 10.1016/j.clpt.2005.06.013.
Article
CAS
PubMed
Google Scholar
Peppa M, Vlassara H: Advanced glycation end products and diabetic complications: a general overview. Hormones. 2005, 4 (1): 28-37.
Article
PubMed
Google Scholar
American Diabetes Association Treatment Algorithm for Type 2 Diabetes. Pharmacist’s Letter/Prescriber’s letter. 2006, 22 (11): 221103-http://faculty.ksu.edu.sa/mahaalrasheed/course/453_454/ADA_Diabetes_Treatment_Algorithm%202006.pdf,
Consumer reports health best buy drugs. The oral diabetes drugs: treating type 2 diabetes. Available from:http://www.consumerreports.org/health/pdf/,
Daousi C, Casson IF, Gill GV, MacFarlane IA, Wilding JPH, Pinkney JH: Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. Postgrad Med J. 2006, 82: 280-284. 10.1136/pmj.2005.039032.
Article
CAS
PubMed
PubMed Central
Google Scholar
Mitri J, Hamdy O: Diabetes medications and body weight. Expert Opin Drug Saf. 2009, 8 (5): 573-584. 10.1517/14740330903081725.
Article
CAS
PubMed
Google Scholar
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR: Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Diabetes Care. 2012, 35: 1364-1379. 10.2337/dc12-0413.
Article
CAS
PubMed
PubMed Central
Google Scholar
Monami M, Iacomelli I, Marchionni N, Mannucci E: Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovas. 2010, 20: 224-235. 10.1016/j.numecd.2009.03.015.
Article
CAS
Google Scholar
Rendell M, Drincic A, Andukuri R: Alogliptin benzoate for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2012, 13 (4): 553-563. 10.1517/14656566.2012.656088.
Article
CAS
PubMed
Google Scholar
Andukuri R, Drincic A, Rendell M: Alogliptin: a new addition to the class of DPP-4 inhibitors. Diabetes Metab Syndr Obes. 2009, 2: 117-126.
Article
CAS
PubMed
PubMed Central
Google Scholar
Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC: Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1–based therapies. Gastroenterology. 2011, 141 (1): 150-156. 10.1053/j.gastro.2011.02.018.
Article
CAS
PubMed
PubMed Central
Google Scholar
Olansky L: Do incretin-based therapies cause acute pancreatitis?. J Diabetes Sci Technol. 2010, 4 (1): 228-229.
Article
PubMed
PubMed Central
Google Scholar
Chopra SS: Industry funding of clinical trials: benefit or bias?. JAMA. 2003, 290 (1): 113-114. 10.1001/jama.290.1.113.
Article
PubMed
Google Scholar
Doucet M, Sismondo S: Evaluating solutions to sponsorship bias. J Med Ethics. 2008, 34: 627-630. 10.1136/jme.2007.022467.
Article
CAS
PubMed
Google Scholar
Walker E, Hernandez AV, Kattan MW: Meta-analysis: its strengths and limitations. Clev Clin J med. 2008, 75 (6): 431-439. 10.3949/ccjm.75.6.431.
Article
Google Scholar